Literature DB >> 34882456

Oncolytic virotherapy as immunotherapy.

Alan Melcher1, Kevin Harrington1, Richard Vile2.   

Abstract

Recognizing immune responses to oncolytic virotherapy opens the way for new combinations.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34882456      PMCID： PMC8961675          DOI： 10.1126/science.abk3436

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  14 in total

1.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Authors:  Georgina V Long; Reinhard Dummer; Omid Hamid; Thomas F Gajewski; Christian Caglevic; Stephane Dalle; Ana Arance; Matteo S Carlino; Jean-Jacques Grob; Tae Min Kim; Lev Demidov; Caroline Robert; James Larkin; James R Anderson; Janet Maleski; Mark Jones; Scott J Diede; Tara C Mitchell
Journal:  Lancet Oncol       Date:  2019-06-17       Impact factor: 41.316

2.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

3.  Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.

Authors:  Gregory K Friedman; James M Johnston; Asim K Bag; Joshua D Bernstock; Rong Li; Inmaculada Aban; Kara Kachurak; Li Nan; Kyung-Don Kang; Stacie Totsch; Charles Schlappi; Allison M Martin; Devang Pastakia; Rene McNall-Knapp; Sameer Farouk Sait; Yasmin Khakoo; Matthias A Karajannis; Karina Woodling; Joshua D Palmer; Diana S Osorio; Jeffrey Leonard; Mohamed S Abdelbaki; Avi Madan-Swain; T Prescott Atkinson; Richard J Whitley; John B Fiveash; James M Markert; G Yancey Gillespie
Journal:  N Engl J Med       Date:  2021-04-10       Impact factor: 91.245

4.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

5.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.

Authors:  Timothy F Cloughesy; Kevin Petrecca; Tobias Walbert; Nicholas Butowski; Michael Salacz; James Perry; Denise Damek; Daniela Bota; Chetan Bettegowda; Jay-Jiguang Zhu; Fabio Iwamoto; Dimitris Placantonakis; Lyndon Kim; Brad Elder; George Kaptain; David Cachia; Yaron Moshel; Steven Brem; David Piccioni; Joseph Landolfi; Clark C Chen; Harry Gruber; Aliz R Rao; Daniel Hogan; William Accomando; Derek Ostertag; Tiffany T Montellano; Thian Kheoh; Fairooz Kabbinavar; Michael A Vogelbaum
Journal:  JAMA Oncol       Date:  2020-12-01       Impact factor: 31.777

7.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Authors:  Jason Chesney; Igor Puzanov; Frances Collichio; Parminder Singh; Mohammed M Milhem; John Glaspy; Omid Hamid; Merrick Ross; Philip Friedlander; Claus Garbe; Theodore F Logan; Axel Hauschild; Celeste Lebbé; Lisa Chen; Jenny J Kim; Jennifer Gansert; Robert H I Andtbacka; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2017-10-05       Impact factor: 44.544

Review 8.  Immune System, Friend or Foe of Oncolytic Virotherapy?

Authors:  Anna C Filley; Mahua Dey
Journal:  Front Oncol       Date:  2017-05-23       Impact factor: 6.244

9.  Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Authors:  Rocio Garcia-Carbonero; Ramon Salazar; Ignacio Duran; Ignacio Osman-Garcia; Luis Paz-Ares; Juan M Bozada; Valentina Boni; Christine Blanc; Len Seymour; John Beadle; Simon Alvis; Brian Champion; Emiliano Calvo; Kerry Fisher
Journal:  J Immunother Cancer       Date:  2017-09-19       Impact factor: 13.751

10.  Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.

Authors:  Jawad Fares; Atique U Ahmed; Ilya V Ulasov; Adam M Sonabend; Jason Miska; Catalina Lee-Chang; Irina V Balyasnikova; James P Chandler; Jana Portnow; Matthew C Tate; Priya Kumthekar; Rimas V Lukas; Sean A Grimm; Ann K Adams; Charles D Hébert; Theresa V Strong; Christina Amidei; Victor A Arrieta; Markella Zannikou; Craig Horbinski; Hui Zhang; Kirsten Bell Burdett; David T Curiel; Sean Sachdev; Karen S Aboody; Roger Stupp; Maciej S Lesniak
Journal:  Lancet Oncol       Date:  2021-06-29       Impact factor: 54.433
View more
  4 in total

Review 1.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

2.  Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.

Authors:  Yinghan Su; Jiang Li; Weidan Ji; Gang Wang; Lin Fang; Qin Zhang; Lin Ang; Min Zhao; Yuan Sen; Lei Chen; Junnian Zheng; Changqing Su; Lunxiu Qin
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

3.  Macrophage Distribution Affected by Virus-Encoded Granulocyte Macrophage Colony Stimulating Factor Combined with Lactate Oxidase.

Authors:  Chia-Chen Hsieh; Ming-Jung Hsieh; Yu-Hsin Wang; Zi-Xian Liao
Journal:  ACS Omega       Date:  2022-06-24

Review 4.  Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.

Authors:  Zhi Zhu; A J Robert McGray; Weijian Jiang; Binfeng Lu; Pawel Kalinski; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2022-10-12       Impact factor: 41.444
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.